Show simple item record

dc.contributor.authorColakoglu, Murat
dc.contributor.authorCobankara, Veli
dc.contributor.authorAkpolat, Tekin
dc.date.accessioned2020-06-21T15:19:00Z
dc.date.available2020-06-21T15:19:00Z
dc.date.issued2007
dc.identifier.issn1060-0280
dc.identifier.issn1542-6270
dc.identifier.urihttps://doi.org/10.1345/aph.1K212
dc.identifier.urihttps://hdl.handle.net/20.500.12712/19797
dc.descriptionWOS: 000248956000027en_US
dc.descriptionPubMed: 17666574en_US
dc.description.abstractOBJECTIVE: To report the novel finding of a significant improvement in Raynaud's I phenomenon symptoms with clonazepam in a patient with systemic sclerosis. CASE SUMMARY: A 45-year-old female with limited scleroderma and chronic renal failure was admitted to our hospital due to hyponatremia (sodium 103 mEq/L). Her hyponatremia was treated by intravenous infusion of NaCl 3%. Clonazepam, which had been prescribed previously for anxiety and insomnia, was discontinued. Three weeks after she was discharged from the hospital, the patient presented with the complaint of increased severity of Raynaud's phenomenon and digital ulcers. She told us that her fingertip ulcers had been healed while she was taking clonazepam and that episodes of Raynaud's phenomenon had increased after discontinuation of the drug. Clonazepam 1 mg twice daily was restarted, and Raynaud's phenomenon and fingertip ulcers resolved within a month. On 2 occasions after that time, we discontinued clonazepam and replaced it with alprazolam, as the patient believed alprazolam was more beneficial in alleviating anxiety. Episodes of Raynaud's phenomenon and new digital ulcers recurred on both of these occasions, and clonazepam was restarted. At the time of writing, no severe episodes of Raynaud's phenomenon or fingertip ulcers have occurred with clonazepam treatment. DISCUSSION: Raynaud's phenomenon and recurrent digital ulcers are a manifestation of vascular disease in patients with systemic sclerosis and lead to pain, impaired function, and tissue loss. Few drugs have previously been shown to affect digital ulcers in the setting of scleroderma. Our patient experienced a significant and sustained improvement in Raynaud's phenomenon and digital ulcers following the initiation of clonazepam. To our knowledge, as of March 2007, this is the first reported use of clonazepam in Raynaud's phenomenon and digital ulcer. While its therapeutic mechanism remains unclear, clonazepam may offer some advantages compared with current agents. CONCLUSIONS: We report a case of Raynaud's phenomenon and digital ulcers responding to clonazepam. Further research is warranted to test the robustness of this preliminary finding.en_US
dc.language.isoengen_US
dc.publisherSage Publications Incen_US
dc.relation.isversionof10.1345/aph.1K212en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectclonazepamen_US
dc.subjectdigital ulcersen_US
dc.subjectRaynaud's phenomenon.en_US
dc.titleEffect of Clonazepam on Raynaud's phenomenon and fingertip ulcers in Sclerodermaen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume41en_US
dc.identifier.issue9en_US
dc.identifier.startpage1544en_US
dc.identifier.endpage1547en_US
dc.relation.journalAnnals of Pharmacotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record